Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Refractory Syringomyelia
NCT06268093Phase 2Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Feb 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in Syringomyelia, sponsored by Xuanwu Hospital. Started Feb 2024; status: recruiting.
02
Drugs
thalidomide
03
Conditions
Syringomyelia
Beyond the preview
Go deeper on NCT06268093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268093.